Several studies and ongoing research are examining whether GLP‑1 medicines such as semaglutide and tirzepatide — substances used in weight‑loss drugs from Novo and Eli Lilly — may, in rare cases, be linked to the unusual eye disease NAION, as previously reported by Life Science Focus.
NAION is a rare condition that affects the small blood vessels in the front part of the optic nerve and can cause visual field defects and sudden vision loss, which may become permanent.
BREAKING